Saturday, June 1, 2013

BeiGene outlicenses Global development and commercialization rights (ex-China) for its novel BRAF inhibitor to Merck KGAA

BeiGene Co., Ltd.  a biotech R&D company in Beijing, and Merck KGaA, Darmstadt, Germany,  have entered into a global licensing, co-development, and commercialization agreement for BeiGene-283.  BeiGene-283 is is a second-generation BRAF inhibitor for the treatment of cancer developed by BeiGene. BRAF inhibtors so far has been successfully tested in metastatic melanoma. There are two BRAF inhibitors that are already marketed - Dabrafenib (GSK) and Vemurafenib (Roche).
BeiGene-283 is currently in preclinical development and is expected to enter clinical development next year. BRAF inhibitors target a protein (BRAF) that is a downstream component of the MAPK* pathway, which is thought to promote cancer cell growth and is dysregulated in a number of human  cancers.

 Terms of the Licensing Agreement

Under the terms of the collaboration, BeiGene will be responsible for the development and commercialization of BeiGene-283 in the People’s Republic of China and Merck KGaA will be responsible for the development and commercialization of BGB-283 for the rest of the world.

BeiGene will receive an undisclosed upfront payment and is eligible to receive further payments of up to US$ 233 million for the achievement of clinical development and potential commercial milestones in both the People’s Republic of China and rest of the world, as well as up to double digit royalties on net sales.